Evidence map›Paper›PMID 41591091›Full record

ReviewNeurology international2026

Modeling Late-Onset Sporadic Alzheimer's Disease Using Patient-Derived Cells: A Review.

Alisar Katbe, Ismaïla Diagne, Gilbert Bernier

Abstract readReview
In one paragraph

Review in Neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alisar KatbeStem Cell and Developmental Biology Laboratory, Maisonneuve-Rosemont Hospital, 5690 Boulevard Rosemont, Montreal, QC H1T 2H2, Canada.ORCID 0009-0007-5305-3543
Ismaïla DiagneStem Cell and Developmental Biology Laboratory, Maisonneuve-Rosemont Hospital, 5690 Boulevard Rosemont, Montreal, QC H1T 2H2, Canada.
Gilbert BernierStem Cell and Developmental Biology Laboratory, Maisonneuve-Rosemont Hospital, 5690 Boulevard Rosemont, Montreal, QC H1T 2H2, Canada.ORCID 0000-0001-9649-6538

Funding

Natural Sciences and Engineering Research Council of Canada RGPIN-2023-04490
6 · The paper itself

Abstract

Late-onset sporadic Alzheimer's disease (LOAD) is the most common form of dementia. The disease is characterized by progressive loss of memory and behavioral changes followed by neurodegeneration of all cortical areas. While the contribution of genetic and environmental factors is important, advanced aging remains the most important disease risk factor. Because LOAD does not naturally occur in most animal species, except humans, studies have traditionally relied on the use of transgenic mouse models recapitulating early-onset familial Alzheimer's disease (EOAD). Hence, the development of more representative LOAD models through reprograming of patient-derived cells into neuronal, glial, and immune cells became a necessity to better understand the disease's origin and pathophysiology. Herein, and focusing on neurons, we review current work in the field and compare results obtained with two different reprograming methods to generate LOAD patient's neuronal cells: the induced pluripotent stem cell and induced neuron technologies. We also evaluate if these models can faithfully mimic cellular and molecular pathologies observed in LOAD patients' brains.

Indexed as

agingAlzheimer’s diseaseepigenomeinduced neuron (iN)induced pluripotent stem cell (iPSC)neuronreprogramming

Identifiers

PMID41591091
PMCPMC12844811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.